CytoMed Therapeutics Finalizes Acquisition of T Cell Technology for Cancer Treatment in China and India

Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.The latest update is out from CytoMed Therapeutics Limited ( (GDTC) ). On November 18, 2025, CytoMed Therapeutics Limited announced the completion of its acquisition of TC BioPharm Limited’s gamma delta T cell technology, TCB-002, to enhance cancer treatment capabilities in China and India. This acquisition aligns with CytoMed’s strategy to establish a non-viral allogeneic gamma delta T cell immunotherapy platform. The technology, which has completed a Phase I clinical trial in Europe and received orphan drug designation by the FDA for Acute Myeloid Leukemia, will be adapted for use in China and India, leveraging new regulatory pathways and cost-effective manufacturing processes. This move replaces previous agreements with Chinese parties and positions CytoMed to capitalize on recent regulatory changes in China, potentially impacting its market positioning and stakeholder interests. The most recent analyst rating on (GDTC) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on CytoMed Therapeutics Limited stock, see the GDTC Stock Forecast page. Spark’s Take on GDTC Stock According to Spark, TipRanks’ AI Analyst, GDTC is a Neutral. GDTC’s overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and persistent losses. Technical analysis further indicates bearish momentum, while valuation metrics highlight ongoing financial struggles with a negative P/E ratio and no dividend yield. To see Spark’s full report on GDTC stock, click here. More about CytoMed Therapeutics Limited CytoMed Therapeutics Limited is a Singapore-based clinical stage biopharmaceutical company focused on developing affordable donor-derived cell-based immunotherapies for treating a broad range of cancers, including both blood and solid tumors. The company was incorporated in 2018 and spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s leading public sector research and development agency. CytoMed leverages proprietary technologies, such as gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create novel allogeneic immunotherapies inspired by the success of CAR-T therapies. Average Trading Volume: 97,702 Technical Sentiment Signal: Sell Current Market Cap: $23M